Paid Clinical Trials Memphis
Discover 562 paid clinical trials in Memphis, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Sponsor:
Cytokinetics
Location:
Code:
NCT06412666
Conditions
Pediatric
Symptomatic Obstructive Hypertrophic Cardiomyopathy
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Aficamten
Placebo
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell TransplantationHaplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
Sponsor:
St. Jude Children's Research Hospital
Location:
Code:
NCT05664126
Conditions
Cytomegalovirus
Adenovirus
Eligibility Criteria
Sex: All
Age: 0 - 18
Healthy Volunteers: Not accepted
Interventions
VST infusion
CliniMACS
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade GliomaSJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Sponsor:
St. Jude Children's Research Hospital
Location:
Code:
NCT04923126
Conditions
Low-Grade Glioma
Recurrent Low-Grade Glioma
Progressive Low-Grade Glioma
Eligibility Criteria
Sex: All
Age: 2 - 24
Healthy Volunteers: Not accepted
Interventions
Mirdametinib
Feasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma SurvivorsFeasibility of Screening for Early Late Effects of Contemporary Therapy in High-Risk Neuroblastoma Survivors
Sponsor:
St. Jude Children's Research Hospital
Location:
Code:
NCT06480526
Conditions
High-risk Neuroblastoma
Eligibility Criteria
Sex: All
Age: 5+
Healthy Volunteers: Not accepted
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyStudy to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Sponsor:
Biohaven Therapeutics Ltd.
Location:
Code:
NCT06309966
Conditions
Focal Epilepsy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BHV-7000
Placebo
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsTo Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
Sponsor:
Cerevance
Location:
Code:
NCT06553027
Conditions
Parkinson Disease
Eligibility Criteria
Sex: All
Age: 30+
Healthy Volunteers: Not accepted
Interventions
CVN424 75 mg
CVN424 150 mg
Placebo
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast CancerTesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer
Sponsor:
Genta Incorporated
Location:
Code:
NCT01609127
Conditions
Locally Advanced Non-resectable Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tesetaxel
Capecitabine